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Abstract
Intestinal metaplasia (IM) is a preneoplastic lesion of the stomach in which there is
transdifferentiation of the gastric mucosa to an intestinal phenotype. The caudal-related
homeobox gene CDX2 encodes an intestine-specific transcription factor crucial for the
regulation of proliferation and differentiation of intestinal cells. In addition, CDX2 is
involved in the induction of IM in the stomach. The aim of this study was to access
the putative involvement of OCT-1 in the induction of CDX2 expression de novo in
gastric mucosa leading to the onset of IM. OCT-1 protein expression was evaluated by
immunohistochemistry in 31 biopsies with chronic gastritis, 15 biopsies with foci of IM
and adjacent gastric mucosa and 42 gastric carcinomas. Furthermore, we evaluated OCT-1
binding by electrophoretic mobility shift assay and activation of the CDX2 promoter by
co-transfecting a CDX2 promoter/reporter construct with an OCT-1 expression vector in
two gastric carcinoma cell lines, GP220 and MKN45. Our results show that OCT-1 is
expressed in chronic gastritis, particularly when it is adjacent to IM and is expressed in
87% of IM foci. Furthermore, 74% of the gastric carcinomas were positive for OCT-1 and
a strong association was observed between OCT-1 expression and intestinal-type carcinoma.
We identified that OCT-1 binds to the CDX2 promoter, although we could not see a
transactivation effect in gastric carcinoma cell lines. In conclusion, we observed increased
OCT-1 expression in IM and in intestinal gastric carcinomas and identified the capacity of
OCT-1 to bind to the CDX2 promoter, although we could not demonstrate a direct effect
of OCT-1 in the transactivation of CDX2.
Copyright  2005 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Intestinal metaplasia (IM) is a preneoplastic lesion of
the stomach in which there is transdifferentiation of
the gastric mucosa to an intestinal phenotype [1,2].
Epidemiological studies have shown that IM is sig-
nificantly associated with an increased risk of gastric
carcinoma: approximately 80% of gastric carcinomas
occur in the setting of IM and the relative risk for
cancer development in the presence of IM is 6.4 [3].
The caudal-related homeobox gene CDX2 encodes
an intestine-specific transcription factor crucial for
the regulation of proliferation and differentiation of
intestinal cells [4–6]. In the adult intestinal epithelium,
CDX2 is expressed mainly in differentiated cells [5,6].
Moreover, when transfected into intestinal epithelial
cell lines, CDX2 was shown to induce cell differenti-
ation and apoptosis [7–9].
In previous studies, we and others have shown that
IM of the stomach as well as a subset of gastric
carcinomas express CDX2 and the intestinal mucin
MUC2, in contrast to the normal gastric mucosa
[2,10–13]. More recently, we and others have shown
that CDX2 regulates the MUC2 gene in gastric cells
through direct binding to its promoter [14,15]. It was
also demonstrated that CDX2 expressed ectopically in
the stomach of transgenic mice is sufficient to induce
intestinal differentiation of the gastric mucosa [16,17].
Hence, CDX2 is one of the most likely candidates to
be involved in the induction of IM of the stomach.
Little is known about the regulation of CDX2 in the
normal intestine and, to the best of our knowledge,
the regulation of aberrant CDX2 expression in gastric
cells has not been addressed.
OCT-1 is a member of the POU homeodomain
family of transcription factors [18] and is expressed
ubiquitously. This protein recognizes the canoni-
cal octamer motif (ATGCAAAT) that regulates the
transcription of various genes, such as the immuno-
globulin genes in B cells [19], several interleukins
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[20,21], and Pit-1 [22]. It has been demonstrated that
OCT-1 is implicated in the activation of the mouse
Cdx2 promoter in pancreatic and intestinal cell lines
[23].
These observations prompted us to investigate
whether OCT-1 could be inducing CDX2 expression
de novo in gastric mucosa, leading to the onset of IM.
We addressed this issue by studying co-localization of
CDX2 and OCT-1 proteins in gastric mucosa, intesti-
nal metaplasia and gastric carcinomas. Furthermore,
we evaluated OCT-1 binding by electrophoretic mobil-
ity shift assay and activation of the CDX2 promoter
by co-transfecting a CDX2 promoter/reporter construct
with an OCT-1 expression vector into two gastric car-
cinoma cell lines, GP220 and MKN45.
Materials and methods
Tissue samples
For the study of OCT-1 expression in gastric mucosa
and in intestinal metaplasia (IM), we used gastric
biopsies from a cohort of asymptomatic or dyspeptic
individuals from northern Portugal (Viana do Castelo),
who volunteered to participate in the endoscopic
examinations and biopsies [24]. Thirty-one biopsies
had gastric mucosa with chronic gastritis without
IM and 15 had IM foci in the setting of chronic
gastritis. Biopsy samples were obtained according to
the regulations of the local ethics committee and with
informed consent of the patients. Forty-two gastric
carcinomas were obtained from patients undergoing
gastrectomy in Hospital S. Joa˜o, Porto, Portugal.
Carcinomas were histologically classified according
to Laure´n’s classification [25]: 18 were intestinal, 15
were diffuse and 9 were atypical.
Immunohistochemistry
Paraffin-embedded samples were serially sectioned
at 4 µm, mounted on gelatin-coated slides, dried
overnight at 37 ◦C and dewaxed with xylene. OCT-1
staining was performed using an anti-OCT-1 poly-
clonal antibody (Labvision). Briefly, slides were boiled
with an antigen retrieval solution (Vector) for 20 min,
incubated with 3% hydrogen peroxide in methanol for
10 min, followed by incubation for 15 min with Ultra
V block solution (Labvision), and finally incubated
overnight at 4 ◦C with the primary antibody diluted
1 : 50 in 5% BSA (v/v). Subsequently, the UltraVi-
sion Detection System, anti-polyvalent HRP (Labvi-
sion) was used following the manufacturer’s protocol.
Slides were developed with DAB, counterstained with
Mayer’s haematoxylin, dehydrated and mounted with
Entellan. Immunohistochemistry for CDX2 was previ-
ously performed in the same cases [10].
Electrophoretic mobility shift assay (EMSA)
Nuclear protein extracts from the gastric carcinoma
cell lines GP202, GP220 and MKN45 were prepared
as previously described [26] and kept at −80 ◦C until
use. Protein content (2 µl of cell extracts) was mea-
sured using the bicinchoninic acid method (Pierce),
as described in the manufacturer’s instruction man-
ual. The sequence of the probe (Proligo) used for
the gel shift is as follows: 5′ TTTATCTTTTAAAAT-
GCAAATTATGTTTCGAGGGG 3′. Radiolabelling of
the probes was performed as previously described [14].
For supershift analysis, 1 µl of a monoclonal anti-
OCT-1 antibody (Santa Cruz Biotechnology, USA)
was added to the proteins and left for 30 min at room
temperature before adding the radiolabelled probe.
Electrophoresis and gel processing were as previously
described [14].
Cell culture
Human gastric carcinoma cell lines GP220 (derived
from a diffuse gastric carcinoma) and MKN45 (derived
from a poorly differentiated gastric carcinoma) were
cultured at 37 ◦C in a humidified 5% CO2 incuba-
tor, maintained in RPMI 1640 medium (with Gluta-
max and 25 mM Hepes) supplemented with 10% fetal
bovine serum and gentamycin (50 µg/ml). The colonic
carcinoma cell line Caco2, used as a control, was cul-
tured in DMEM under the conditions described above.
Transient transfection assays
Cell lines were seeded at 2.5 × 105/well in 24-well
plates. Co-transfections were performed the next day
by mixing 0.8 µg of the pGL3(−871/−1)Cdx2 pro-
moter construct and 0.4 µg of the OCT-1 expres-
sion vector (a kind gift from Professor Winship
Herr, Cold Spring Harbor Laboratory, NY) with Tfx-
50 reagent (Promega) (Tfx-50 : DNA ratio of 4 : 1)
in 200 µl serum-free medium. Cells were incubated
with the transfection mixture for 1 h at 37 ◦C, fol-
lowed by addition of 400 µl complete medium. Total
cell extracts were prepared after 48 h incubation at
37 ◦C using 1× reporter lysis buffer (Promega), as
described in the manufacturer’s instruction manual.
20 µl cell extract were mixed with 100 µl luciferase
assay reagent (Promega) to determine luciferase activ-
ity in a 1450 Microbeta luminescence counter (Wal-
lac). β-galactosidase activity was measured using
50 µl cell extract.
Statistical analysis
The StatView 5.0 computer program was employed
in the statistical analysis of data. Distributions were
compared by χ2 and Student’s t-test and significance
was assumed whenever p values were <0.05.
Results
Expression of OCT-1 in the gastric mucosa with
and without IM and in gastric carcinomas
Expression of OCT-1 in gastric mucosa with chronic
gastritis was observed in the nuclei of cells in the
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Figure 1. Gastric mucosa with and without intestinal metaplasia (IM) and gastric carcinomas immunostained for OCT-1.
(A) OCT-1 is expressed in the neck region of the gastric mucosa without IM and is absent from the surface and the deep glands.
(B) IM shows OCT-1 expression predominantly in the bottom of the crypts (insert in B). (C) Intestinal gastric carcinoma with
OCT-1 expression and (D) diffuse gastric carcinoma without OCT-1 expression
proliferative region (Figure 1). OCT-1 was present in
the gastric mucosa adjacent to IM in a high percentage
of cases, 75% in the antrum, 71% in the incisura
and 75% in the body region (Table 1), whereas in
gastric mucosa without IM it was observed in a smaller
percentage of cases, 22% in the antrum, 21% in the
incisura and 38% in the body region (Table 1). IM
lesions were positive for OCT-1 in 87% of the cases,
in particular in the proliferative region, as observed in
the normal gastric mucosa (Table 1, Figure 1). In all
J Pathol 2005; 207: 396–401
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Table 1. Expression of OCT-1 in 31 gastric mucosae with chronic gastritis, in 15 foci of IM and adjacent gastric
mucosae, obtained from the antrum, incisura and body regions of the stomach
Mucosa without IM
Antrum Incisura Body Mucosa with IM
+ (%) − (%) + (%) − (%) + (%) − (%) + (%) − (%)
Cases with IM 3 (75) 1 (25) 5 (71) 2 (29) 3 (75) 1 (25) 13 (87) 2 (13)
Cases without IM 2 (22) 7 (78) 3 (21) 11 (79) 3 (38) 5 (63) — —
Table 2. Expression of OCT-1 in a series of gastric carcinomas,
according to Laure´n’s classification and to the expression of
CDX2
OCT-1
Parameters
Negative
n (%)
Positive
n (%)
p
Value
Laure´n’s classification (n = 42)
Intestinal (n = 18) 3 (17) 15 (83)
Diffuse (n = 15) 8 (53) 7 (47)
Atypical (n = 9) 0 (0) 9 (100) 0.008
CDX2 expression (n = 42)
Positive (n = 23) 6 (26) 17 (74)
Negative (n = 19) 5 (26) 14 (74) n.s.
cases some inflammatory cells were also positive for
OCT-1.
We also analysed OCT-1 expression in 42 gas-
tric carcinomas. Overall, 74% of the gastric carcino-
mas were positive for OCT-1. We could not identify
an association between OCT-1 expression and CDX2
expression in our series of carcinomas (Table 2). How-
ever, we observed a strong association between OCT-1
expression and the histological type of gastric carci-
noma (Table 2). The majority of the gastric carcinomas
of the intestinal type were positive for OCT-1 (83%),
whereas 53% of the diffuse gastric carcinomas were
negative (Table 2, Figure 1).
EMSA
We performed EMSA to evaluate whether OCT-1
binds to the OCT-1 consensus sequence present in
the CDX2 promoter (Figure 2A). Incubation of the
OCT-1 probe located at −416/−409 with nuclear pro-
teins from GP220, GP202 and MKN45 gastric carci-
noma cell lines led to the formation of three com-
plexes (Figure 2B), which were shown to be specific,
since pre-incubation with 50× molar excess of the
cold probe resulted in the absence of retarded bands
(Figure 2B). Binding of OCT-1 was confirmed by a
total supershift of complex 1 upon addition of anti-
OCT-1 antibody in the reaction mixture (Figure 2B).
Role of the transcription factor OCT-1 on CDX2
promoter activity in gastric and colonic carcinoma
cell lines
We co-transfected MKN45, GP220 and Caco2 cell
lines with the CDX2 promoter construct −871/−1 and
a vector encoding OCT-1 (pCG–OCT-1). We could
not observe transactivation of the CDX2 promoter
by the OCT-1 transcription factor in the gastric cell
lines (Figure 2C). The Caco2 colonic cell line showed
higher OCT-1 transactivation when compared to gas-
tric cell lines (Figure 2C).
Discussion
We observed that OCT-1 is expressed in non-
metaplastic gastric mucosa in the proliferative region,
and that its expression is increased in the mucosa
adjacent to IM foci. We further identified OCT-1
expression in 87% of IM foci, mostly in the pro-
liferative region, where it co-localized with CDX2.
These observations support our hypothesis that OCT-1
might trigger aberrant expression of CDX2 in gastric
cells, thus leading to an intestinal transdifferentiation
process. Our initial assumption was based on sev-
eral previous studies: OCT-1 transactivates the mouse
Cdx2 promoter in the intestinal cell line Caco-2 and
in the pancreatic cell line InR1-G9 [23]. Furthermore,
OCT-1 protein expression is increased in response to
genotoxic stress in multiple human cell lines [27].
Therefore, we hypothesized that OCT-1 might be up-
regulated in an inflammatory setting such as chronic
atrophic gastritis, where IM develops. The increased
OCT-1 expression in IM and in gastric mucosa in the
vicinity of IM is thus in agreement with our hypoth-
esis. However, the presence of OCT-1 in the prolifer-
ative region of non-metaplastic mucosa with chronic
gastritis suggests that it is not, at least by itself, suffi-
cient to trigger CDX2 expression.
In gastric carcinoma cases we did not observe a sig-
nificant association between OCT-1 and CDX2 expres-
sion: OCT-1 is observed in 76% of the carcinomas,
whereas CDX2 is observed in 55% [10]. This suggests
that CDX2 expression might be lost during progression
of gastric carcinomas from IM. IM is considered a risk
factor for gastric carcinoma, based on the results of
various epidemiological studies [3] and it has recently
been shown that transgenic mice that express CDX2
ectopically in the stomach, in addition to developing
IM [16,17], later develop gastric polyps with features
of invasive carcinomas [28]. The significant associa-
tion of OCT-1 with intestinal-type gastric carcinomas
as well as with IM suggests that, directly or via CDX2,
OCT-1 is playing a role in gastric carcinogenesis that
J Pathol 2005; 207: 396–401
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Figure 2. Study of the involvement of OCT-1 in the regulation of CDX2 promoter activity. (A) Schematic representation of
the OCT-1 putative binding site at −416/−409 in the CDX2 promoter region. (B) EMSA performed with nuclear extracts from
GP220, GP202 and MKN45 gastric carcinoma cell lines and an OCT-1 radiolabelled probe. Lane 1 is the probe alone; lanes 2–4
are the nuclear extracts incubated with the radiolabelled probe; lane 5 is the competition assay performed with 50× excess
of cold probe; and lane 6 is a supershift assay performed with an antibody against OCT-1. DNA–protein complexes and the
supershifted complex (SS Oct1) are indicated by arrows. (C) Regulation of CDX2 promoter activity in the gastric carcinoma cell
lines MKN45 and GP220 and in the intestinal cell line Caco2 by OCT- 1. CDX2 promoter construct −871/−1 was co-transfected
with pCG-OCT-1 expression vector and with the empty vector pCG for control. The values obtained in cells transfected with
the empty vector are referred to as 1. The results are means ± SD and represent two separate experiments done in triplicate.
∗p < 0.02
leads to intestinal-type gastric carcinomas. Loss of
CDX2 expression in gastric carcinomas that arise from
IM is in agreement with the fact that CDX2 expres-
sion decreases in human colorectal cancers in relation
to tumour grade and is lost in minimally differentiated
colon carcinomas [29,30].
In an attempt to clarify the capacity of OCT-1 to
transactivate CDX2 in gastric cells, we performed
luciferase and EMSA studies that showed that, despite
having the capacity to bind to the CDX2 promoter,
OCT-1 does not efficiently transactivate CDX2 in our
model. This observation is in contrast to what was
previously described in colonic and pancreatic cell
lines [23] and the same trend was observed in the
present study in Caco2. The results we obtained in
gastric cell lines may stem from cell-type specificity
in the regulation of CDX2 by OCT-1 due to the
participation of co-factors. In fact, and lending support
to this interpretation, OCT-1 is known to interact with
co-factors to activate different proteins, such as with
STAT5 in the activation of cyclin D1 [31] and with
Bob1 to stimulate transcription of immunoglobulin
genes [32].
In conclusion, we observed significantly increased
OCT-1 expression in IM and in intestinal gastric
carcinomas and identified the capacity of OCT-1
to bind to the CDX2 promoter, although we could
not demonstrate a direct effect of OCT-1 in the
transactivation of CDX2.
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